See the DrugPatentWatch profile for keytruda

Keytruda, a drug manufactured by Merck & Co., was approved by the U.S. Food and Drug Administration (FDA) for use in cancer care on September 4, 2014 [1]. Keytruda, also known as pembrolizumab, is a type of medication called an immune checkpoint inhibitor, which helps the body's immune system fight cancer [2].

The FDA approved Keytruda for the treatment of advanced melanoma, a type of skin cancer, in adults and children aged 12 years and older [1]. The drug was initially approved for use in patients whose cancer had progressed after other treatments and for those with a specific type of advanced melanoma [1]. Since its initial approval, Keytruda has received additional approvals from the FDA for the treatment of several other types of cancer [2].

According to DrugPatentWatch.com, Keytruda is protected by several patents, with the first patent expiring in 2028 [3]. This means that generic versions of Keytruda are not expected to be available until at least 2028 [3].

In summary, Keytruda was approved by the FDA for use in cancer care on September 4, 2014, and is currently approved for the treatment of several types of cancer. Keytruda is protected by several patents, with the first patent expiring in 2028.

Sources:

* [1] U.S. Food and Drug Administration. (2014). FDA approves new treatment for advanced skin cancer. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-advanced-skin-cancer>.
* [2] National Cancer Institute. (2021). Pembrolizumab. <https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab>.
* [3] DrugPatentWatch.com. (2021). Keytruda (pembrolizumab) patent landscape. <https://www.drugpatentwatch.com/patent/keytruda-pembrolizumab/>.